MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.02
+0.14%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$27.78
From 52W high−40.80%
Volume3.76M
Market cap$2.48B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$27.78
From 52W high
−40.80%
Volume
3.76M
Market cap
$2.48B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
P/E (TTM)
—
RSI (14)
50.9
MomentumView details →
1D Return
+0.14%
YTD Return
−23.22%
SummaryUpdated Jun 1, 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Radnor, Pennsylvania. The company went public in February 2023 and focuses on developing innovative therapies for hypertension and associated cardiovascular diseases. Mineralys is currently advancing its lead drug candidate, lorundrostat, through multiple Phase III clinical trials targeting patients with uncontrolled and resistant hypertension, representing a significant unmet medical need affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.40d agoMineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer to lead medical and late-stage clinical activities.40d ago